cyclohexanol has been researched along with Cryptogenic Fibrosing Alveolitis in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Albers, R; Ayala, L; Bahmanyar, S; Bai, A; Benish, B; Bennett, B; Blease, K; Bodine, T; Cathers, BE; Celeridad, M; Chamberlain, P; Clareen, SS; D'Sidocky, N; Delgado, M; Delker, SL; Fan, R; Giegel, D; Hegde, S; Hilgraf, R; Katz, J; Khatsenko, O; Lachowitzer, J; McCarrick, M; Moghaddam, M; Muir, J; Nadolny, L; Plantevin Krenitsky, V; Raymon, H; Sapienza, J; Satoh, Y; Shirley, MA; Tang, Y; Wright, J; Xu, L | 1 |
1 other study(ies) available for cyclohexanol and Cryptogenic Fibrosing Alveolitis
Article | Year |
---|---|
Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor.
Topics: Administration, Oral; Animals; Catalytic Domain; Cyclohexanols; Dogs; Enzyme Activation; Enzyme Inhibitors; Haplorhini; Idiopathic Pulmonary Fibrosis; Inhibitory Concentration 50; MAP Kinase Kinase 4; Models, Molecular; Molecular Structure; Purines; Rats; Structure-Activity Relationship | 2012 |